1. Generics Bulletin
  2. >>Business

Here’s What Competition Looks Like In India’s Humira Biosimilars Market

 
• By Anju Ghangurde

Competition may be just readying to jump in and gnaw into Humira’s share in Europe later this year, but the Indian market for biosimilar adalimumab already has more than half a dozen players, with distinct pricing characteristics. Scrip takes a peek into the competitive market.

Leadership
INDIA'S HUMIRA BIOSIMILAR MARKET ALREADY HAS SEVERAL BRANDS VYING FOR SHARE

The Indian market for biosimilar versions of AbbVie Inc.'s blockbuster biologic Humira (adalimumab) appears to have witnessed significant activity – there are an estimated seven brands already jostling for share. The segment has also seen an expanding patient pool and improved access amid interesting pricing dynamics.

First off the block was Zydus Cadila’s biosimilar adalimumab (marketed as Exemptia); launched in December 2014, Exemptia claimed to be a "fingerprint match" with the originator product in terms of safety, purity and potency. It was followed by Torrent Pharmaceuticals Ltd.’s version of adalimumab (marketed as Adfrar) launched in 2016

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Generics Bulletin

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By Dean Rudge

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Medicines UK Welcomes NHS England’s Best-Value Biologics Biosimilar Adoption Framework

 
• By Adam Zamecnik

Reflecting on recent initiatives by NHS England and the MHRA, the newly renamed trade body Medicines UK has welcomed efforts in promoting the use of biosimilars in Britain.